Navigation Links
New Drug No Substitute for Standard Blood-Clot Therapy
Date:9/12/2007

t 4 percent for those on a placebo. However, those who received an additional six months of idraparinux had a higher incidence of bleeding complications -- 3.1 percent versus 0.9 percent for those on a placebo.

"The long duration of action for idraparinux is a benefit, but it's also a hazard, because there's no antidote," said Dr. Edward L. Amorosi, a hematologist at the New York University Medical Center.

"It appears to be a more effective anti-thrombotic for DVT, but it's not safe enough to make it standard treatment," he added.

Buller said that Sanofi-Aventis is conducting research on pulmonary embolism treatment with a newer version of idraparinux, and that results should be available within a year. The new trial should help answer the question of whether or not the findings in the current pulmonary embolism trial were a statistical anomaly or not, he said.

More information

To learn more about blood clots, visit the U.S. National Library of Medicine.



SOURCES: Harry Buller, M.D., professor and chairman, department of vascular medicine, Academic Medical Center, Amsterdam, the Netherlands; Edward L. Amorosi, M.D., hematologist, New York University Medical Center's Clinical Cancer Center, and associate professor, New York University School of Medicine, New York City; Sept. 13, 2007, New England Journal of Medicine


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. ATG useful in transplant patients as substitute for steroids
2. Fat Substitutes
3. Studies Show Combination Drugs As A Poor Substitute For Anti-Coagulants In Stroke
4. Salt Substitute Could Cut Heart Disease Risk
5. Measures to Streamline Marketing of Breast-Milk Substitutes
6. Light Therapy Fights Depression With Sun Substitute
7. Genetically Altered Cells Prevent Lethal Infections in Substituted Skin
8. Substitute for Chemotherapy Tested by Canadian Scientists
9. US Climate Plan Must Not Substitute UN Treaties: China
10. New standards for Human Research Safety
11. Angioplasty Should be the Standard
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)...rter financial results -, LAVAL, QC, July 25 /PRN...DAQ: DDSS) today announced that it will host a con... to discuss its second quarter 2008,financial resu... financial,results via news release at approximate...nce call by telephone, dial 416-646-3095 or,1-800-...
(Date:7/25/2008)...erweight or obese is not only a personal issue tha... issue that impacts other people in society. A new...eveals that the extra Medicare cost associated wit...ant financial burden on tax payers, costing up to ...current Medicare population. , The article,s fi...
(Date:7/25/2008)...Fourth Annual Physician On-Call Pay ...swire/ -- Sullivan, Cotter and Associates, Inc.,ha...on-call pay rates and,practices, the 2008 Physicia...th data from 132 healthcare organizations nationwi...ates paid for 33 physician specialty areas along,w...
(Date:7/25/2008)...ire/ -- Sagent Pharmaceuticals, Inc.,a privately-...nced that it,has launched amiodarone HCl injection...e treatment and prophylaxis of frequently recurrin...table ventricular,tachycardia -- a potentially lif...arone HCl injection will be available immediately ...
Breaking Medicine News(10 mins):Health News:Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET) 2Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 2Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 3Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 3
... U.S. is getting metamorphosed into luxurious buil...ipments which may offer good patient hospitality b...g to non-accessible of poor patients to these luxu...s changing from a semi-private health system to co...
...licy to Briton citizen could increase advertising ...y is aimed at // reducing the waiting time of th...eople can make their own choice of treatment at an... their comfortable location and choice. Health Sec...
...hat is mainly present in pain relievers. Recently ...ing the // clinicians complaining about over dosa...re of the liver but about 50% of these cases are u...yl, Contac, Excedrin, Robitussin, Nyquil and Sinut...
...ty of California have now established a very stron...ure, or end-stage renal disease. So if you are thi...away, as there is no time to lose. // "There are...ure, but it hasn't been appreciated much that kidn...
Other Medicine News:Health News:Painkillers Lead To Liver Failure 2
(Date:7/24/2008)... New JIT Enrollment Program Speeds Oncology... Pharmatech, Inc., a Research Management,Organizat...ceutical,companies to provide research and site ma...the Just-in-Time (JIT) enrollment strategy. The ne...: follicular Non-Hodgkin,s,Lymphoma, Metastatic Br...
(Date:7/24/2008)... NEW YORK, July 24 /- Mac...y announced results of a Phase 2 clinical trial,in...multi-center,open-label efficacy and safety study...treatment of onychomycosis (nail fungus). The comp...complete cure" defined as,negative mycology (negat...
(Date:7/23/2008)... - Nexavar is First Approved Systemic Therapy to... Calif., July 23 /-,Bayer H..., Inc. (Nasdaq:,ONXX) today announced that The New...a Phase 3 trial demonstrating that Nexavar(R) (sor...th by 31 percent in patients with,unresectable hep...
(Date:7/23/2008)... SEATTLE, July 23 /- Sound Pharmace...g Application with the FDA for the clinical,testin...prevention of,chemotherapy induced hearing loss or... SPI-3005, will be tested in advanced stage lung c...platinum based chemotherapy.,This marks the second...
Breaking Medicine Technology:Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials 2MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 2MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 3MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 4MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 5The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 3The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 4The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 5The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 6Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer 2Rocky water source 3607 1Rocky water source 3607 2Sex offenders register provides limited protection for children 21576 1Sex offenders register provides limited protection for children 21576 2Raloxifene Cuts Risk of Certain Type of Breast Cancer 21573 1Raloxifene Cuts Risk of Certain Type of Breast Cancer 21573 2Harris Corporations Jim Traficant Addresses Florida Agency for Health Care Administration 21570 1Harris Corporations Jim Traficant Addresses Florida Agency for Health Care Administration 21570 2
LigaSure system generator, bipolar only. Designed to permanently seal vessels and tissue bundles.
Sabre 180 is a powerful niche generator.
Sabre 180 is a powerful niche generator.
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator.
Medicine Products: